Prokaryotic RNA virus vaccine platform for avian immunity

Overview

The prokaryotic RNA virus vaccine platform is a groundbreaking solution designed to enhance avian immunity through engineered MS2 bacteriophage virus-like particles (VLPs). This innovative approach encapsulates infectious bronchitis virus (IBV) mRNA and displays multiple IBV antigens, promoting both cellular and humoral immune responses in chickens. The technology is safe, eliminating reversion or replication risks, and is suitable for mass oral or nasal administration. Additionally, it is cost-effective, easy to scale, and can be stored long-term through lyophilization, making it ideal for large-scale deployment.

Technical specifications

• Engineered MS2 VLPs: Nonpathogenic, lack viral genetic material, ensuring safety.
• DIVA-compatible: Enables differentiation of infected versus vaccinated animals.
• Mass administration: Suitable for oral or nasal delivery in poultry.
• Flexible antigen presentation: Can adapt to new virus variants rapidly.
• Cost-effective production: Economical to produce, scale up, and purify.
• Lyophilization: Enables long-term storage and stability.

Technology readiness level

This technology is at TRL 2, having been proven in concept with foundational research demonstrating its immunogenicity and safety in animal models. Future validation steps include optimizing antigen presentation, scaling production, and confirming efficacy and safety in chickens.